文献速递浆细胞疾病

新型HDAC6抑制剂上调多发性骨髓瘤细胞CD38表达属类效应并可增强达雷妥尤单抗疗效

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
PubMed 文献 · Leukemia · 2020-04-29

多发性骨髓瘤(MM)仍不可治愈,复发难治患者亟需有效治疗。本研究探讨HDAC抑制剂ricolinostat上调MM细胞CD38表达并增强CD38靶向治疗的作用,发现ricolinostat显著增加CD38 RNA水平及表面表达,与达雷妥尤单抗联用可增强MM细胞裂解;下一代HDAC6抑制剂ACY-241和WT-161也观察到类似CD38升高,提示该上调作用为类效应。

要点

  • ricolinostat显著增加MM细胞CD38 RNA水平及表面表达。
  • ricolinostat与达雷妥尤单抗联用诱导增强的MM细胞裂解。
  • ACY-241和WT-161也观察到类似CD38升高,提示为类效应。

核心结论

  • HDAC6抑制剂上调MM细胞CD38表达属类效应,并可增强CD38靶向免疫治疗疗效,为概念验证性发现。

研究设计与样本

  • 采用定量逆转录聚合酶链反应和流式细胞术检测CD38 RNA水平及表面表达,并用直接随机光学重建超分辨显微成像验证CD38分子在细胞膜上的分布。

主要发现

  • ricolinostat显著增加MM细胞CD38 RNA水平及CD38表面表达;超分辨显微成像证实CD38分子在细胞膜上呈均匀分布。
  • ricolinostat与达雷妥尤单抗联用诱导增强的MM细胞裂解。
  • 下一代HDAC6抑制剂ACY-241和WT-161也观察到类似的CD38水平升高,提示HDAC6抑制剂上调MM细胞CD38表达为类效应。

临床怎么用

  • 作者认为该概念验证结果展示了HDAC6抑制剂与CD38靶向免疫治疗联用于MM治疗的潜在获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment. The efficiency of daratumumab might be improved by combining it with synergistic anti-MM agents. We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies. Using quantitative reverse transcription polymerase chain reaction and flow cytometry, we observed that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells. Super-resolution microscopy imaging of MM cells by direct stochastic optical reconstruction microscopy confirmed this rise with molecular resolution and revealed homogeneous distribution of CD38 molecules on the cell membrane. Particularly important is that combining ricolinostat with daratumumab induced enhanced lysis of MM cells. We also evaluated next-generation HDAC6 inhibitors (ACY-241, WT-161) and observed similar increase of CD38 levels suggesting that the upregulation of CD38 expression on MM cells by HDAC6 inhibitors is a class effect. This proof-of-concept illustrates the potential benefit of combining HDAC6 inhibitors and CD38-directed immunotherapy for MM treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. García-Guerrero E, Götz R, Doose S, et al. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 2020. PMID: 32350373. doi:10.1038/s41375-020-0840-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。